The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Table 5

The PASI, VAS, and DLQI scores of various ages.

	Treatment group
Variable/age	20–30	31–40	41–50	Up to 51
PASI baseline	9.94 ± 1.73	8.17 ± 2.21	6.22 ± 0.57	6.04 ± 0.77
PASI week 4	9.46 ± 1.75	7.77 ± 2.21	5.67 ± 0.56	5.42 ± 0.61
PASI week 8	7.80 ± 1.20	6.70 ± 1.95	4.98 ± 0.50	4.44 ± 0.47
PASI week 12	5.14 ± 0.47	4.50 ± 1.11	3.82 ± 0.42	3.42 ± 0.35
VAS baseline	64.00 ± 5.09	57.50 ± 12.50	59.11 ± 8.80	51.28 ± 10.30
VAS week 4	57.60 ± 5.59	52.00 ± 11.53	52.11 ± 8.84	42.28 ± 9.29
VAS week 8	52.00 ± 6.34	41.75 ± 12.37	44.55 ± 8.43	31.00 ± 7.89
VAS week 12	44.40 ± 7.33	31.75 ± 11.52	34.33 ± 8.26	21.14 ± 6.62
DLQI baseline	12.60 ± 0.74	14.75 ± 3.01	12.00 ± 1.71	9.57 ± 1.42
DLQI week 4	11.40 ± 0.5	13.75 ± 2.65	11.00 ± 1.54	8.28 ± 1.32
DLQI week 8	10.20 ± 0.48	10.50 ± 2.10	9.00 ± 1.59	7.14 ± 10.1
DLQI week 12	8.20 ± 0.78	7.75 ± 1.22	6.66 ± 1.79	4.57 ± 0.96
Control group
PASI baseline	7.94 ± 0.91	5.87 ± 0.46	6.14 ± 1.34	7.02 ± 1.37
PASI week 4	7.94 ± 0.91	5.800 ± 0.49	5.98 ± 1.18	7.02 ± 1.37
PASI week 8	7.94 ± 0.91	5.80 ± 0.49	5.58 ± 0.81	7.02 ± 1.37
PASI week 12	7.94 ± 0.91	5.73 ± 0.51	4.96 ± 0.38	7.02 ± 1.37
VAS baseline	51.00 ± 10.29	47.50 ± 8.66	50.00 ± 14.23	60.50 ± 10.69
VAS week 4	50.40 ± 10.12	46.46 ± 8.56	48.20 ± 13.10	60.00 ± 10.63
VAS week 8	50.40 ± 10.12	45.84 ± 8.34	44.40 ± 10.51	60.00 ± 10.63
VAS week 12	50.40 ± 10.12	45.61 ± 8.26	42.80 ± 9.63	60.00 ± 10.63
DLQI baseline	8.60 ± 1.50	10.15 ± 1.96	8.80 ± 2.17	11.50 ± 2.32
DLQI week 4	8.60 ± 1.50	9.92 ± 1.77	8.80 ± 2.17	11.50 ± 2.32
DLQI week 8	8.60 ± 1.50	9.92 ± 1.77	8.80 ± 2.17	11.50 ± 2.32
DLQI week 12	8.60 ± 1.50	8.79 ± 1.09	7.60 ± 1.12	11.50 ± 2.32